The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects.
about
Systemic availability of itraconazole in lung transplantationFood interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteersTherapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveLimited-sampling strategy models for itraconazole and hydroxy-itraconazole based on data from a bioequivalence studyThe use of intermittent itraconazole therapy for superficial mycotic infections: a review and update on the 'one week' approach.Voriconazole: a new triazole antifungal.Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic malignancyItraconazole: an effective oral antifungal for onychomycosis.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Role of itraconazole in haematology/oncology.Soluble itraconazole in tablet form using disordered drug delivery approach: critical scale-up considerations and bio-equivalence studies.Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.Guideline for diagnosis, prophylaxis and treatment of invasive fungal infection post burn injury in China 2013Antifungal therapeutic drug monitoring: established and emerging indications.Absorption mechanism of DHP107, an oral paclitaxel formulation that forms a hydrated lipidic sponge phase.Opportunistic invasive fungal infections: diagnosis & clinical management.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Triazole antifungal agents in invasive fungal infections: a comparative review.Itraconazole: Precautions regarding drug interactions and bioavailability.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Treatment of aspergillosis with itraconazole.Antifungal drugs combinations: a patent review 2000-2015.Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers.Potential use of a simplified method for determination of itraconazole levels in plasma and esophageal tissue by using high-performance liquid chromatography.Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction.It's on the tip of my tongue.Fluconazole-induced symptomatic phenytoin toxicity.Effect of food on the pharmacokinetics of multiple-dose oral voriconazoleAlternate-day dosing of itraconazole in healthy adult cats.Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites.Antibody-Conjugated Silica-Modified Gold Nanorods for the Diagnosis and Photo-Thermal Therapy of Cryptococcus neoformans: an Experiment In Vitro.Pharmacology of Systemic Antifungal Agents
P2860
Q24675285-DEF8FE7C-0A62-4AC1-BA86-25EC4F82D497Q24681178-142EBF7A-F24C-493A-9ED0-50D1CD86DAE3Q27009221-CEA59193-586C-4D30-ADC9-FAAB72402BEBQ31943628-1E2151BD-B619-4CB8-99B4-8E45E5AA02B8Q33749026-969F11CA-F463-4712-86D4-FE3887DAEF1AQ33917339-09037809-DF8F-4A07-ADCA-A4AA77F01793Q33981794-4A5F58DC-93FF-43C4-9CAC-A5907C7AE893Q34201565-703159AF-2500-4F85-B62F-04D6E6411544Q34505582-EF6349BF-F7EF-4415-B5C8-BB4B8069FEDFQ35070963-7329EFED-837D-4047-8030-C26BCED3F222Q36636520-C276FE0C-60D3-4931-9916-42FE3F76A253Q37115829-8D5989C9-BBE5-4A75-A4EA-D31DC5A58BD3Q37233505-E70324B5-4821-46FB-9E2B-85C46B1AB5CEQ37310029-E474E0DE-EE44-4D51-833E-4EE8BD857C5CQ37571909-35B83EC8-6377-4A0D-9982-823578DCD49CQ37726198-531FCB46-3892-4F71-81D6-0E0B836A2FA0Q37904672-C57211AA-F839-4D6F-8C68-09D6F2CE93D4Q37964703-DAB539C0-DE3E-46B0-89F8-278232E7BF61Q37985918-FA16DDA3-509C-452E-AD41-F0E76BD8DEA6Q38193337-B2540FEA-1F87-4B68-B80C-D65E23BA970CQ38567823-0364090F-BE77-4854-AC30-42C4A335EDDEQ38712653-1F43F82C-5B5F-49F6-ABC8-1DDA96B595E3Q39558155-736221F7-6269-4EE8-A251-4F7BFE989E5EQ39779411-29F44C98-66CD-4A60-8B92-7FF5733FF776Q40183320-21215C2F-C5B6-42AF-A658-2766BF6EE108Q40479467-3FD63037-FAE0-4BC2-82C9-73EB8ACDD7DCQ40748053-5AB2853C-3DA7-495B-B13C-0C0689B45330Q42284203-A535DDEE-0F7A-48FC-8934-E6AEF80731F6Q44856929-BED45CA1-FDE7-4E97-A6AE-178C4A6DBE65Q50924422-E0F961E9-E995-47DD-9C11-A7B069446224Q52930705-8BFEDD93-0033-425E-AA39-3A4EB3B29B52Q57533011-6BBD4790-E4CC-4933-B46D-C7E4AB64F3E4
P2860
The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh-hant
name
The effects of food and dose o ...... aconazole in healthy subjects.
@en
The effects of food and dose o ...... aconazole in healthy subjects.
@nl
type
label
The effects of food and dose o ...... aconazole in healthy subjects.
@en
The effects of food and dose o ...... aconazole in healthy subjects.
@nl
prefLabel
The effects of food and dose o ...... aconazole in healthy subjects.
@en
The effects of food and dose o ...... aconazole in healthy subjects.
@nl
P2093
P356
P1476
The effects of food and dose o ...... aconazole in healthy subjects.
@en
P2093
A Van Peer
G Gauwenbergh
J Heykants
R Gasparini
R Woestenborghs
P2888
P304
P356
10.1007/BF00558308
P577
1989-01-01T00:00:00Z